EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment

Anne Ravix iD, Anaïs Maillat, Eva Choong, Chantal Csajka, Monia Guidi, Francesco Ceppi iD

Pediatric Blood & Cancer · 2026-04 · 73 (4)

DOI: 10.1002/1545-5017.70167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 25.02.2026. Verfasst von Anne Ravix und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerlan…. Hauptthemen laut MEDLINE: Mercaptopurine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Thioguanine, Antimetabolites, Antineoplastic. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. The pro‐drug 6‐mercaptopurine (6‐MP), essential during maintenance, is converted into active 6‐thioguanine (6‐TGN) and toxic 6‐methylmercaptopurine (6‐MMP) metabolites, resulting in marked variability in efficacy and toxicity. 6‐MP therapy is further limited by poor adherence, variable absorption, and complex metabolism. Allopurinol is sometimes used to correct skewed metabolism, though its precise clinical role remains unclear.

Methods

This study aimed to develop population pharmacokinetic (popPK)‐based strategies to optimize 6‐MP dosing in children and improve therapeutic outcomes. A popPK model was developed using 6‐MMP and 6‐TGN concentrations from the pediatric oncology cohort. Model‐based simulations in 1000 virtual patients were performed to explore optimized dosing strategies, with and without allopurinol, aiming to reach the therapeutic target (6‐MMP

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MercaptopurinePrecursor Cell Lymphoblastic Leukemia-LymphomaThioguanineAntimetabolites, AntineoplasticModels, BiologicalThionucleotidesHumansChildChild, PreschoolFemaleMaleAllopurinolInfantAdolescent

Stichwörter der Autor:innen

6‐mercaptopurineacute lymphoblastic leukemiaallopurinoldose optimizationpediatric

Substanzen

MercaptopurineThioguanine6-methylthiopurineAntimetabolites, AntineoplasticAllopurinolThionucleotides

Autor:innen und Institutionen

  • Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Division of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
  • Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
  • Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.

ORCID-Profile: Anne Ravix, Francesco Ceppi

Zitieren

APA

Ravix, A., Maillat, A., Choong, E., Csajka, C., Guidi, M., & Ceppi, F. (2026). Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment. Pediatric Blood & Cancer, 73(4). https://doi.org/10.1002/1545-5017.70167

Vancouver

Ravix A, Maillat A, Choong E, Csajka C, Guidi M, Ceppi F. Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment. Pediatric Blood & Cancer. 2026;73(4). doi:10.1002/1545-5017.70167

BibTeX
@article{Ravix2026,
  author = {Ravix, Anne and Maillat, Anaïs and Choong, Eva and Csajka, Chantal and Guidi, Monia and Ceppi, Francesco},
  title = {Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {4},
  doi = {10.1002/1545-5017.70167}
}
Kostenlos starten →